Opinion|Videos|October 11, 2024
Key End Points in Clinical Trials
Key Takeaways
- Progression-free survival and overall survival are key endpoints in multiple myeloma trials, crucial for evaluating treatment efficacy.
- Stringent eligibility criteria in clinical trials may limit their applicability to real-world scenarios, necessitating more inclusive designs.
Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As a provider, what primary end points in clinical trials are most clinically significant, and how can multiple myeloma clinical trials be changed to be more applicable to or inclusive of real-world scenarios?
Advertisement
Related to this article
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
For as long as practicing oncology pharmacists have been in the field, multiple myeloma carried a standard caveat: treatable, not curable—now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5